Botanix Pharmaceuticals Limited BXPHF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 6.14M | 6.00M | 5.42M | 5.40M | 1.73M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.14M | 6.00M | 5.42M | 5.40M | 1.73M |
| Cost of Revenue | 2.98M | 2.91M | 1.96M | 1.95M | 820.90K |
| Gross Profit | 3.16M | 3.09M | 3.46M | 3.45M | 912.40K |
| SG&A Expenses | 15.43M | 15.09M | 14.10M | 14.06M | 16.86M |
| Depreciation & Amortization | 401.20K | 392.20K | 389.30K | 388.10K | 367.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.81M | 18.39M | 16.45M | 16.40M | 18.05M |
| Operating Income | -12.67M | -12.39M | -11.03M | -11.00M | -16.32M |
| Income Before Tax | -12.98M | -12.69M | -10.89M | -10.86M | -17.78M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.98M | -12.69M | -10.89M | -10.86M | -17.78M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.98M | -12.69M | -10.89M | -10.86M | -17.78M |
| EBIT | -12.67M | -12.39M | -11.03M | -11.00M | -16.32M |
| EBITDA | -12.27M | -11.99M | -10.64M | -10.61M | -15.95M |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Average Basic Shares Outstanding | 2.37B | 2.37B | 1.96B | 1.96B | 1.87B |
| Average Diluted Shares Outstanding | 2.37B | 2.37B | 1.96B | 1.96B | 1.87B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |